Alnylam Pharmaceuticals, Inc. (ALNY) — Analysis Summary
Alnylam Pharmaceuticals, Inc. (ALNY) has a market cap of $38.46B with year-over-year revenue growth of +65.2%. Net margin stands at 8.4%. The stock trades at a P/E ratio of 122.6.
Key Takeaways
- Revenue changed +65.2% year-over-year
- Net margin of 8.4%
- P/E ratio of 122.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ALNY posted revenue growth of +65.2% and trades at a P/E of 122.6.
Alnylam Pharmaceuticals, Inc. (ALNY)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Interest coverage at 2.0x — limited headroom for earnings decline
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
2,500
Headquarters
CAMBRIDGE, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.